ibuprofen has been researched along with Amyloid Deposits in 7 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
| Excerpt | Relevance | Reference |
|---|---|---|
| "The brain in Alzheimer's disease (AD) shows a chronic inflammatory response characterized by activated glial cells and increased expression of cytokines and complement factors surrounding amyloid deposits." | 5.31 | Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. ( Ashe, KH; Beech, W; Chen, P; Chu, T; Cole, GM; Frautschy, SA; Lim, GP; Teter, B; Tran, T; Ubeda, O; Yang, F, 2000) |
| "Ibuprofen treatment reduced levels of lipid peroxidation, tyrosine nitration, and protein oxidation, demonstrating a dramatic effect on oxidative damage in vivo." | 1.38 | Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease. ( Cramer, PE; Herrup, K; Jiang, Q; Lamb, BT; Landreth, GE; Reed-Geaghan, E; Szabo, A; Varvel, NH; Wilkinson, BL, 2012) |
| "Ibuprofen treatment significantly reduced microglia area in cortex and hippocampus but not beta-amyloid burden." | 1.35 | CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. ( Cenacchi, V; Facchinetti, F; Hutter-Paier, B; Imbimbo, BP; Lanzillotta, A; Pizzi, M; Villetti, G; Volta, R; Windisch, M, 2009) |
| "Curcumin was a better Abeta40 aggregation inhibitor than ibuprofen and naproxen, and prevented Abeta42 oligomer formation and toxicity between 0." | 1.33 | Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. ( Ambegaokar, SS; Begum, AN; Chen, PP; Cole, GM; Frautschy, SA; Glabe, CG; Kayed, R; Lim, GP; Simmons, MR; Ubeda, OJ; Yang, F, 2005) |
| "Epidemiological studies have suggested that the chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the relative risk of Alzheimer's disease (AD)." | 1.32 | In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. ( Agdeppa, ED; Barrio, JR; Cole, GM; Huang, SC; Kepe, V; Liu, J; Petri, A; Satyamurthy, N; Small, GW, 2003) |
| "The brain in Alzheimer's disease (AD) shows a chronic inflammatory response characterized by activated glial cells and increased expression of cytokines and complement factors surrounding amyloid deposits." | 1.31 | Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. ( Ashe, KH; Beech, W; Chen, P; Chu, T; Cole, GM; Frautschy, SA; Lim, GP; Teter, B; Tran, T; Ubeda, O; Yang, F, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, C | 1 |
| Qin, H | 1 |
| Zheng, R | 1 |
| Wang, Y | 1 |
| Yan, T | 1 |
| Huan, F | 1 |
| Han, Y | 1 |
| Zhu, W | 1 |
| Zhang, L | 1 |
| Imbimbo, BP | 1 |
| Hutter-Paier, B | 1 |
| Villetti, G | 1 |
| Facchinetti, F | 1 |
| Cenacchi, V | 1 |
| Volta, R | 1 |
| Lanzillotta, A | 1 |
| Pizzi, M | 1 |
| Windisch, M | 1 |
| Wilkinson, BL | 1 |
| Cramer, PE | 1 |
| Varvel, NH | 1 |
| Reed-Geaghan, E | 1 |
| Jiang, Q | 1 |
| Szabo, A | 1 |
| Herrup, K | 1 |
| Lamb, BT | 1 |
| Landreth, GE | 1 |
| Agdeppa, ED | 1 |
| Kepe, V | 1 |
| Petri, A | 1 |
| Satyamurthy, N | 1 |
| Liu, J | 1 |
| Huang, SC | 1 |
| Small, GW | 1 |
| Cole, GM | 4 |
| Barrio, JR | 1 |
| Yang, F | 3 |
| Lim, GP | 3 |
| Begum, AN | 1 |
| Ubeda, OJ | 1 |
| Simmons, MR | 1 |
| Ambegaokar, SS | 1 |
| Chen, PP | 1 |
| Kayed, R | 1 |
| Glabe, CG | 1 |
| Frautschy, SA | 3 |
| Morihara, T | 1 |
| Teter, B | 2 |
| Boudinot, S | 1 |
| Boudinot, FD | 1 |
| Chu, T | 1 |
| Chen, P | 1 |
| Beech, W | 1 |
| Tran, T | 1 |
| Ubeda, O | 1 |
| Ashe, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252] | Phase 1 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Curcumin and Yoga Exercise Effects in Veterans at Risk for Alzheimer's Disease[NCT01811381] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-20 | Active, not recruiting | ||
| A Phase II, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of Two Doses of Curcumin C3 Complex Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease[NCT00099710] | Phase 2 | 33 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| Open Label,Crossover,Pilot Study to Assess the Efficacy & Safety of Perispinal Admin.of Etanercept(Enbrel®) in Comb.w/Nutritional Supplements vs. Nutritional Supplements Alone in Subj. w/Mild to Mod. Alzheimer's Disease Receiving Std. Care.[NCT01716637] | Phase 1 | 12 participants (Anticipated) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for ibuprofen and Amyloid Deposits
| Article | Year |
|---|---|
A new approach for Alzheimer's disease treatment through P-gp regulation via ibuprofen.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; ATP Binding Cassette Transporte | 2018 |
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2009 |
Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cells, C | 2012 |
In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Autoradiogr | 2003 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoate | 2005 |
Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models.
Topics: Acute-Phase Proteins; alpha 1-Antichymotrypsin; Alzheimer Disease; Amyloid Precursor Protein Secreta | 2005 |
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloidosis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Disease Mod | 2000 |